

Washington University School of Medicine

Digital Commons@Becker

Open Access Publications

10-1-2019

Transcriptional and epigenetic regulation of cardiac electrophysiology

Jesus Jimenez

Stacey L Rentschler

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs



Transcriptional and Epigenetic Regulation of Cardiac Electrophysiology

Jesus Jimenez¹ · Stacey L. Rentschler¹

Received: 1 October 2018 / Accepted: 16 July 2019 / Published online: 25 July 2019
© The Author(s) 2019

Abstract

Spatiotemporal gene expression during cardiac development is a highly regulated process. Activation of key signaling pathways involved in electrophysiological programming, such as Notch and Wnt signaling, occurs in early cardiovascular development and these pathways are reactivated during pathologic remodeling. Direct targets of these signaling pathways have also been associated with inherited arrhythmias such as Brugada syndrome and arrhythmogenic cardiomyopathy. In addition, evidence is emerging from animal models that reactivation of Notch and Wnt signaling during cardiac pathology may predispose to acquired arrhythmias, underscoring the importance of elucidating the transcriptional and epigenetic effects on cardiac gene regulation. Here, we highlight specific examples where gene expression dictates electrophysiological properties in both normal and diseased hearts.

Keywords Electrophysiology · *HEY2* · *KCNIP2* · Epigenetics · Histone modification

Introduction

The human heart starts beating spontaneously about 3 weeks after fertilization [1]. To reach this remarkable milestone, embryonic cells must differentiate into various cardiac cell types and maintain their identity through regulated spatiotemporal gene expression [2–5]. Evidence is emerging that differential susceptibility to cardiac arrhythmias may arise from these early embryonic programming events, mediated in part through chamber and regional-specific enhancer activity and chromatin patterning [6]. Key mechanisms of transcriptional and epigenetic regulation of cardiovascular development and pathological states include post-translational histone modification, non-coding RNA, and DNA methylation. Here, we will highlight how chamber-specific transcriptional responses and histone modifications collectively function to activate or repress transcriptional activity and ultimately direct gene expression, which contributes

to chamber specificity in electrical homeostasis, as well as electrical “remodeling” in disease.

Theory of Metabolic Memory

Modifications to the nucleosome, the basic unit of chromatin consisting of DNA coiled around histones, controls packaging of DNA and regulates access of transcription factors to the DNA [7]. There are at least 15 types of functional histone modifications which can occur, and the most commonly studied modifications in the heart are histone methylation/demethylation and acetylation/deacetylation [4]. Various activating and repressing histone modifications dictate gene transcription, and chromatin dysregulation can result in pathological cardiac gene expression.

Epigenetic mechanisms have been hypothesized to be a crucial interface between genetic and environmental factors to explain the theory of metabolic memory in diseases such as diabetes. Metabolic memory in diabetes focuses on the interrelationship between stressors (i.e., hyperglycemia, oxidative stress, chronic inflammation), which induce mechanisms that persist after the stressor is removed (i.e., controlled hyperglycemia) [8]. In a study by Brasacchio et al., even just transient exposure to hyperglycemia resulted in sustained activation of NF- κ B (nuclear factor-kappa B), a key regulator of

✉ Stacey L. Rentschler
stacey.rentschler@wustl.edu

¹ Cardiovascular Division, Department of Medicine, and Department of Developmental Biology, Washington University School of Medicine, 309 McDonnell Science Bldg, 660 South Euclid Ave, Campus Box 8103, St Louis, MO 63110, USA

inflammatory gene expression, which may contribute to the later development of diabetic complications [9]. Similarly, it is well known that many cardiac injuries can predispose to future cardiac arrhythmias, and much work to date has focused on understanding this arrhythmogenic substrate at the tissue level, including tools to assess fibrosis, though the underlying cellular mechanisms are less well understood [10]. Clinically, it is well known that arrhythmias such as atrial fibrillation beget further atrial fibrillation, and perhaps a similar mechanism for electrical “remodeling” and arrhythmia predisposition may also be a crucial interface between genetic predisposition and acquired factors including age, hypertension, and diabetes. When these electrical changes are long-lasting after removal of the stressor, this “remodeling” may be best understood as cardiac “reprogramming.”

Our group has shown in a clinically relevant murine heart failure model, encompassed by progressive heart failure via transverse aortic constriction (TAC) plus small apical myocardial infarction, that Notch signaling is transiently reactivated in the adult heart, including reactivation in atrial and ventricular cardiomyocytes [11, 12]. Though activation of Notch within embryonic cardiomyocytes would lead to cardiomyocyte cell division, the effects in the adult heart are quite distinct. Instead of kick-starting a regenerative process, Notch activation in adult murine myocytes results in sustained alteration to ion channel gene expression and electrical currents which predisposes to arrhythmias [12]. It will be interesting to understand how this signaling process relates to ventricular arrhythmias which are frequently associated with heart failure. Indeed, Weinheimer et al. built on the clinically relevant heart failure mouse model described above and followed this with “debanding” to remove the stressor, thus restoring left-ventricular (LV) structure. However, LV function was only partially recovered and there was incomplete reversal of transcriptional changes associated with heart failure, which correlates with what is often seen clinically in heart failure patients [13]. Specifically, we see that after an initial heart failure diagnosis and following guideline directed medical therapy, some patients can partially recover cardiac function with resolution of heart failure symptoms. However, these patients often regress and are re-hospitalized, indicative of persistent mechanisms that trigger heart failure. Current work is focused on understanding the role of Notch signaling in this process, which we hope may ultimately result in better ways to predict which patients are most at-risk for life-threatening arrhythmias.

Cardiac Chamber-Specific Histone Modifications and Electrophysiology

Embryologically, the left and right ventricles arise from the first and second heart fields, respectively, and are exposed to distinct signaling pathways during cardiac development

[8]. This programming in the form of epigenetic “memory” may ultimately underlie some of the baseline electrical differences seen within various regions of the adult heart. A review by Molina et al. illustrates electrophysiological features and differences between the right ventricle (RV) and LV [14]. For example, the RV expresses lower levels of cardiac Na⁺ channels and higher levels of cardiac K⁺ channels when compared with the LV, which contributes to slower conduction in the RV [15]. Specifically, these differences can provide a critical substrate for developing life-threatening arrhythmias that originate in the right ventricle including the ventricular outflow tract in disorders such as Brugada syndrome, where inherited mutations of the gene that encodes Na⁺ channels (*SCN5A*) or the direct Notch signaling pathway target *HEY2* (Hairy/enhancer-of-split related with YRPW motif protein 2), among other mutations, can result in ventricular arrhythmias and sudden cardiac death [16, 17].

In addition to regulating baseline physiology, developmental programming may also dictate the differential response to stress in various regions of the heart, a response often referred to as reactivation of the “fetal gene program.” An early study to distinguish cardiac-specific epigenetic regulation of gene expression in normal murine hearts used chromatin immunoprecipitation (ChIP) analysis to compare LV versus RV expression levels of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP). In normal wild-type mice, the group found increased levels of Histone 3 lysine 4 dimethylation (H3K4me2) and Histone 3 lysine 9 acetylation (H3K9ac) with concomitantly higher expression levels of ANP and BNP in the LV compared to RV [18]. In a separate study by Hohl et al., the group compared human non-failing and failing hearts where they showed upregulation of ANP and BNP in failing LV compared to non-failing LV without changes in H3K9ac or H3K4me2. However, there were reductions in the gene-silencing marks (H3K9me2 and H3K9me3), illustrating distinct mechanisms for gene regulation in the pathological state [19]. To this end, it would be interesting to study histone modifications in arrhythmogenic right ventricular cardiomyopathy where RV dysfunction predominates, given that there is greater upregulation of BNP in the RV compared with the LV in these patients [20]. These studies reveal maladaptive reactivation of fetal gene programs can occur in a chamber-specific manner and highlight that there may be distinct mechanisms for gene regulation via histone modification during homeostasis and after cardiac stressors [21].

The Notch signaling pathway regulates multiple aspects of embryogenesis, from processes as diverse as cardiac structure to programming cardiac electrophysiologic properties [22]. We have previously shown that developmental Notch gain of function (GOF) mice have increased action potential duration (APD) in the LV [11]. Interestingly, in Notch-activated mice,

Hey2 expression levels are upregulated in the LV, whereas *Hey2* expression levels are downregulated in the RV. These gene expression changes are associated with increased Histone H3 lysine 4 trimethylation (H3K4me3) at the *Hey2* promoter in the LV, while there is loss of the H3K4me3 marks in the RV. Furthermore, the key transcriptional cofactor RBP-J (recombination signal binding protein for immunoglobulin kappa J region), is dynamically bound to the proximal *Hey2* promoter and also to an enhancer specifically within the LV but not in the RV [11]. Figure 1a shows a schematic of the “priming” of the LV that occurs during early cardiac development, which may later facilitate the expression of *Hey2* in adulthood following a specific trigger that induces Notch. Collectively, these results demonstrate that chamber-specific histone modifications can result in distinct electrical phenotypes and regulation of gene expression.

More recently, we demonstrate how embryonic programming via the Wnt signaling pathway also regulates electrophysiology in a chamber-specific manner [23, 24]. It has long been postulated that *Hey2* is regulated by mechanisms in addition to Notch signaling within the ventricles. We demonstrate for the first time that *Hey2* is a direct Wnt target only in the RV and not the LV, which may have relevance to our understanding of RV-specific arrhythmias [23]. Using both Wnt gain and loss-of-function approaches, additional genes regulating cardiac electrophysiology, *Gjal* (gap junction alpha-1, encodes connexin 43) and *Scn5a* (encodes $\text{Na}_v1.5$ protein), were shown to be differentially regulated. Gene expression changes result in slower conduction velocity in both the Wnt gain and loss-of-function RV, but not LV, though the mechanism of slowed conduction is distinct in these models. Indeed, the chamber-specific gene expression changes predispose the mice to ventricular tachycardia with physiologic stimulation of the RV only. ChIP analysis of wild-type embryonic hearts demonstrates enrichment of the active H3K27ac mark in a *Hey2* enhancer region shown to be bound by the Wnt effector β -catenin in the RV only, while a distinct *Hey2* enhancer demonstrates H3K27ac enrichment in the embryonic LV. Since *Hey2* regulates important electrical properties within the RV, this example highlights how a chamber-specific understanding of embryonic transcriptional and epigenetic programming may help us to better understand arrhythmias which occur later in life. Figure 1b represents a model of the “priming” of the RV that occurs in early cardiac development, which may later facilitate the expression of *HEY2* in adulthood following a specific trigger where Wnt signaling is reactivated.

Histone Modification in Cardiomyopathy

Two hallmark electrophysiological findings in failing hearts include conduction slowing and action potential prolongation. Electrophysiological heterogeneity within the heart

presupposes the dysregulation of multiple key components of the action potential, including downregulation of repolarizing K^+ currents (I_{K1} , I_{to} , I_{Kr} , I_{Ks}), alterations to depolarizing Ca^{2+} currents ($I_{\text{Ca-L}}$) and Ca^{2+} transporters (NCX, SERCA2a), and downregulation of depolarizing Na^+ currents (I_{Na}). Connexin 43 is a key cardiac gap junction protein that can be downregulated or improperly distributed which also results in slowed conduction [25, 26].

Several studies have focused on the downregulation of repolarizing K^+ currents, offering an illustrative example of the interplay between heart failure, electrophysiologic remodeling, and histone modifications. In the heart, *KCNIP2* (potassium channel interacting protein 2, which encodes the KChIP2 protein) interacts with the subfamily of voltage-gated potassium channel (Kv4) to increase current density, accelerate recovery from inactivation, and slow inactivation kinetics [27]. Collectively, changes in KChIP2 levels alters the fast component of the cardiac transient outward potassium current (I_{to}) and contributes to APD prolongation and conduction slowing in both humans as well as canine models of heart failure [28, 29]. As discussed above, cardiac injuries and subsequent progression to heart failure reactivates Notch signaling in mouse models of heart failure, with concomitant downregulation of *Kcnip2*, and loss of H3K4me3 associated with dynamic RBP-J binding to the *Kcnip2* promoter [11]. Bolstering the significance of these findings, a study by Stein et al. demonstrated that loss of the same H3K4me3 methylation site through adult-inducible deletion of PAX-interacting protein 1 (PTIP), an essential cofactor for H3K4 methylation, resulted in reduced *Kcnip2* expression levels [30]. In addition, PTIP-deficient mice exhibited APD prolongation with reduced I_{to} and development of premature ventricular beats. Therefore, understanding how post-translational histone modifications are regulated is relevant to understanding cardiac electrophysiology, especially in the setting of heart failure.

Downregulation of *KCNIP2* has been shown to be a consistent finding across the spectrum of human cardiomyopathies. Exciting work recently demonstrates that KChIP2 protein not only contributes to I_{to} , but it also regulates a transcriptional network in the heart. In a paper by Nassal et al., KChIP2 was shown to regulate microRNAs (miRNA) important for conduction and maintenance of electrical stability through KChIP2 binding to the miR-34b/c promoter region in the nucleus, supporting the notion that KChIP2 can behave as a transcriptional repressor [31]. In both neonatal rat cardiomyocytes exposed to phenylephrine as a mimic of neuro-hormonal overload and samples of human heart failure tissue, downregulation of KChIP2 and concomitant upregulation of miR-34b/c was observed. Restoration of KChIP2 expression levels not only reverted miR-34b/c levels back to baseline, but also restored channel function and impeded reentrant ventricular arrhythmias in a cell culture




Fig. 1 Schematic of chamber-specific “priming” and differential *HEY2* expression levels. **a** Canonical Notch signaling regulates early cardiac development mediated by nuclear translocation of the Notch intracellular domain (NICD), forming a complex with the DNA-binding transcription factor RBP-J (recombination signal binding protein for immunoglobulin kappa J region), MAML (mastermind-like protein), and other coactivators (CoA) to form the Mastermind-containing transcriptional complex at the enhancer region (blue). In the adult during homeostasis, RBP-J is bound to this blue enhancer element in the left ventricle (LV), but not the right ventricle (RV). Upon a pathologic stimulus that reactivates Notch signaling, expression of *HEY2* is upregulated only in the “primed” LV, whereas there is no change in *HEY2* expression levels in the RV. **b** Canonical Wnt signaling regulates early cardiac development that is mediated by nuclear translocation of β -catenin (β -cat) forming a complex with the DNA-binding T-cell factor (TCF) and other coactivators at a distinct *HEY2* enhancer region (yellow). In the adult during homeostasis, β -catenin is bound to the yellow enhancer in the RV, but not the LV. In reciprocal fashion to Notch signaling, a stimulus that reactivates Wnt signaling results in *HEY2* upregulation in the “primed” RV, but no change in *HEY2* expression in the LV

model. Given the importance of *KCNIP2* in regulating transcription and electrical remodeling in heart failure, understanding how it is regulated will be of clinical importance.

More broadly, several exciting studies offer a blueprint for understanding the role of epigenetics in heart failure. Studies by Rosa-Garrido et al. used genome-wide chromatin conformation capture (Hi-C) of isolated adult cardiomyocytes from a TAC heart failure mouse model to reveal alterations in chromatin compartmentalization and looping, demonstrating chromatin remodeling in conjunction with decreased enhancer interactions in heart failure [32]. To support these findings, the team generated a knock-out mouse of CTCF, a chromatin structural protein with key roles in regulating genome architecture and accessibility [33]. CTCF knock-out mice not only mirrored the chromatin remodeling findings of the TAC heart failure mice but also recapitulated the cardiac dysfunction seen in heart failure. As a clinical correlation, CTCF itself was found to be downregulated in end-stage heart failure patients requiring left-ventricular assist devices. Not surprisingly, CTCF knock-out mice did not reveal changes in H3K27me3 nor in H3K4me3, indicating the effects occurred via an alternative epigenetic mechanism to histone modifications and illustrating the critical role CTCF plays in chromatin regulation and heart failure.

Conclusion

Signaling pathways active during cardiac development program cardiomyocyte identity. In the adult, these developmental pathways can be reactivated in disease states during pathologic remodeling where they can bind to chamber-specific enhancer and promoter regions and are associated with specific histone modifications. These mechanisms of gene

regulation coordinate differential transcription of genes such as *HEY2* and *KCNIP2* in a chamber-specific manner, which may contribute to deadly ventricular arrhythmias.

Acknowledgements This study was supported by Grants T32 HL007081 (J. Jimenez), R01 HL130212 (S. Rentschler), and UG3HL141800 (S. Rentschler) from the National Institutes of Health. Rentschler holds a Career Award for Medical Scientists from the Burroughs Wellcome Fund.

Compliance with Ethical Standards

Conflict of interest The authors have no conflict of interest to declare.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

- Carlson BM (2014) Human Embryology and Developmental Biology. Elsevier, Philadelphia
- Chang CP, Bruneau BG (2012) Epigenetics and cardiovascular development. *Annu Rev Physiol* 74:41–68
- Preissl S, Schwaderer M, Raulf A, Hesse M, Gruning BA, Kobele C, Backofen R, Fleischmann BK, Hein L, Gilsbach R (2015) Deciphering the epigenetic code of cardiac myocyte transcription. *Circ Res* 117:413–423
- van der Harst P, de Windt LJ, Chambers JC (2017) Translational perspective on epigenetics in cardiovascular disease. *J Am Coll Cardiol* 70:590–606
- Nehrenberg T, Gilsbach R, Preissl S, Schnick T, Hein L (2014) Epigenetics in cardiac development, function, and disease. *Cell Tissue Res* 356:585–600
- Sivagangabalan G, Nazzari H, Bignolais O, Maguy A, Naud P, Farid T, Masse S, Gaborit N, Varro A, Nair K, Backx P, Vigmond E, Nattel S, Demolombe S, Nanthakumar K (2014) Regional ion channel gene expression heterogeneity and ventricular fibrillation dynamics in human hearts. *PLoS ONE* 9:e82179
- Kornberg RD (1974) Chromatin structure: a repeating unit of histones and DNA. *Science* 184:868–871
- Testa R, Bonfigli AR, Prattichizzo F, La Sala L, De Nigris V, Ceriello A (2017) The “Metabolic Memory” theory and the early treatment of hyperglycemia in prevention of diabetic complications. *Nutrients* 9:E437
- Brasacchio D, Okabe J, Tikellis C, Balcerzyk A, George P, Baker EK, Calkin AC, Brownlee M, Cooper ME, El-Osta A (2009) Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. *Diabetes* 58:1229–1236
- Nguyen TP, Qu Z, Weiss JN (2014) Cardiac fibrosis and arrhythmogenesis: the road to repair is paved with perils. *J Mol Cell Cardiol* 70:83–91
- Khandekar A, Springer S, Wang W, Hicks S, Weinheimer C, Diaz-Trelles R, Nerbonne JM, Rentschler S (2016) Notch-mediated epigenetic regulation of voltage-gated potassium currents. *Circ Res* 119:1324–1338

12. Qiao Y, Lipovsky C, Hicks S, Bhatnagar S, Li G, Khandekar A, Guzy R, Woo KV, Nichols CG, Efimov IR, Rentschler S (2017) Transient notch activation induces long-term gene expression changes leading to sick sinus syndrome in mice. *Circ Res* 121:549–563
13. Weinheimer CJ, Kovacs A, Evans S, Matkovich SJ, Barger PM, Mann DL (2018) Load-dependent changes in left ventricular structure and function in a pathophysiologically relevant murine model of reversible heart failure. *Circ Heart Fail* 11:e004351
14. Molina CE, Heijman J, Dobrev D (2016) Differences in left versus right ventricular electrophysiological properties in cardiac dysfunction and arrhythmogenesis. *Arrhythm Electrophysiol Rev* 5:14–19
15. Martin CA, Siedlecka U, Kemmerich K, Lawrence J, Cartledge J, Guzadhur L, Brice N, Grace AA, Schwiening C, Terracciano CM, Huang CL (2012) Reduced Na(+) and higher K(+) channel expression and function contribute to right ventricular origin of arrhythmias in Scn5a^{+/-} mice. *Open Biol* 2:120072
16. Bezzina CR, Barc J, Mizusawa Y, Remme CA, Gourraud JB, Simonet F, Verkerk AO, Schwartz PJ, Crotti L, Dagradi F, Guicheney P, Fressart V, Leenhardt A, Antzelevitch C, Bartkowiak S, Borggreffe M, Schimpf R, Schulze-Bahr E, Zumhagen S, Behr ER, Bastiaenen R, Tfelt-Hansen J, Olesen MS, Kaab S, Beckmann BM, Weeke P, Watanabe H, Endo N, Minamino T, Horie M, Ohno S, Hasegawa K, Makita N, Nogami A, Shimizu W, Aiba T, Froguel P, Balkau B, Lantieri O, Torchio M, Wiese C, Weber D, Wolswinkel R, Coronel R, Boukens BJ, Bezieau S, Charpentier E, Chatel S, Despres A, Gros F, Kyndt F, Lecointe S, Lindenbaum P, Portero V, Violleau J, Gessler M, Tan HL, Roden DM, Christoffels VM, Le Marec H, Wilde AA, Probst V, Schott JJ, Dina C, Redon R (2013) Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death. *Nat Genet* 45:1044–1049
17. Veerman CC, Podliesna S, Tadros R, Lodder EM, Mengarelli I, de Jonge B, Beekman L, Barc J, Wilders R, Wilde AAM, Boukens BJ, Coronel R, Verkerk AO, Remme CA, Bezzina CR (2017) The brugada syndrome susceptibility gene HEY2 modulates cardiac transmural ion channel patterning and electrical heterogeneity. *Circ Res* 121:537–548
18. Mathiyalagan P, Chang L, Du XJ, El-Osta A (2010) Cardiac ventricular chambers are epigenetically distinguishable. *Cell Cycle* 9:612–617
19. Hohl M, Wagner M, Reil JC, Muller SA, Tauchnitz M, Zimmer AM, Lehmann LH, Thiel G, Bohm M, Backs J, Maack C (2013) HDAC4 controls histone methylation in response to elevated cardiac load. *J Clin Invest* 123:1359–1370
20. Cao ZP, Xue JJ, Zhang Y, Tian MH, Xiao Y, Jia YQ, Zhu BL (2017) Differential expression of B-type natriuretic peptide between left and right ventricles, with particular regard to sudden cardiac death. *Mol Med Rep* 16:4763–4769
21. He A, Gu F, Hu Y, Ma Q, Ye LY, Akiyama JA, Visel A, Pennacchio LA, Pu WT (2014) Dynamic GATA4 enhancers shape the chromatin landscape central to heart development and disease. *Nat Commun* 5:4907
22. Rentschler S, Harris BS, Kuznekoff L, Jain R, Manderfield L, Lu MM, Morley GE, Patel VV, Epstein JA (2011) Notch signaling regulates murine atrioventricular conduction and the formation of accessory pathways. *J Clin Invest* 121:525–533
23. Li G, Khandekar A, Yin T, Hicks SC, Guo Q, Takahashi K, Lipovsky CE, Brumback BD, Rao PK, Weinheimer CJ, Rentschler SL (2018) Differential Wnt-mediated programming and arrhythmogenesis in right versus left ventricles. *J Mol Cell Cardiol* 123:92–107
24. Gillers BS, Chiplunkar A, Aly H, Valenta T, Basler K, Christoffels VM, Efimov IR, Boukens BJ, Rentschler S (2015) Canonical wnt signaling regulates atrioventricular junction programming and electrophysiological properties. *Circ Res* 116:398–406
25. Aiba T, Tomaselli GF (2010) Electrical remodeling in the failing heart. *Curr Opin Cardiol* 25:29–36
26. Akar FG, Nass RD, Hahn S, Cingolani E, Shah M, Hesketh GG, DiSilvestre D, Tunin RS, Kass DA, Tomaselli GF (2007) Dynamic changes in conduction velocity and gap junction properties during development of pacing-induced heart failure. *Am J Physiol Heart Circ Physiol* 293:H1223–1230
27. An WF, Bowlby MR, Betty M, Cao J, Ling HP, Mendoza G, Hinson JW, Mattsson KI, Strassle BW, Trimmer JS, Rhodes KJ (2000) Modulation of A-type potassium channels by a family of calcium sensors. *Nature* 403:553–556
28. Zicha S, Xiao L, Stafford S, Cha TJ, Han W, Varro A, Nattel S (2004) Transmural expression of transient outward potassium current subunits in normal and failing canine and human hearts. *J Physiol* 561:735–748
29. Niwa N, Nerbonne JM (2010) Molecular determinants of cardiac transient outward potassium current (I_{to}) expression and regulation. *J Mol Cell Cardiol* 48:12–25
30. Stein AB, Jones TA, Herron TJ, Patel SR, Day SM, Noujaim SF, Milstein ML, Klos M, Furspan PB, Jalife J, Dressler GR (2011) Loss of H3K4 methylation destabilizes gene expression patterns and physiological functions in adult murine cardiomyocytes. *J Clin Invest* 121:2641–2650
31. Nassal DM, Wan X, Liu H, Maleski D, Ramirez-Navarro A, Moravec CS, Ficker E, Laurita KR, Deschenes I (2017) KChIP2 is a core transcriptional regulator of cardiac excitability. *Elife* 6:e17304
32. Rosa-Garrido M, Chapski DJ, Schmitt AD, Kimball TH, Karbassi E, Monte E, Balderas E, Pellegrini M, Shih TT, Soehalim E, Liem D, Ping P, Galjart NJ, Ren S, Wang Y, Ren B, Vondriska TM (2017) High-resolution mapping of chromatin conformation in cardiac myocytes reveals structural remodeling of the epigenome in heart failure. *Circulation* 136:1613–1625
33. Monte E, Rosa-Garrido M, Karbassi E, Chen H, Lopez R, Rau CD, Wang J, Nelson SF, Wu Y, Stefani E, Lusis AJ, Wang Y, Kurdastani SK, Franklin S, Vondriska TM (2016) Reciprocal regulation of the cardiac epigenome by chromatin structural proteins Hmgb and Ctcf: Implic Transcript I Regul. *J Biol Chem* 291:15428–15446

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.